Therapeutic Implications of miRNAs for Muscle-Wasting Conditions
MicroRNAs (miRNAs) are small, non-coding RNA molecules that are mainly involved in translational repression by binding to specific messenger RNAs. Recently, miRNAs have emerged as biomarkers, relevant for a multitude of pathophysiological conditions, and cells can selectively sort miRNAs into extrac...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/11/3035 |
| _version_ | 1827677043487145984 |
|---|---|
| author | Laura Yedigaryan Maurilio Sampaolesi |
| author_facet | Laura Yedigaryan Maurilio Sampaolesi |
| author_sort | Laura Yedigaryan |
| collection | DOAJ |
| description | MicroRNAs (miRNAs) are small, non-coding RNA molecules that are mainly involved in translational repression by binding to specific messenger RNAs. Recently, miRNAs have emerged as biomarkers, relevant for a multitude of pathophysiological conditions, and cells can selectively sort miRNAs into extracellular vesicles for paracrine and endocrine effects. In the overall context of muscle-wasting conditions, a multitude of miRNAs has been implied as being responsible for the typical dysregulation of anabolic and catabolic pathways. In general, chronic muscle disorders are associated with the main characteristic of a substantial loss in muscle mass. Muscular dystrophies (MDs) are a group of genetic diseases that cause muscle weakness and degeneration. Typically, MDs are caused by mutations in those genes responsible for upholding the integrity of muscle structure and function. Recently, the dysregulation of miRNA levels in such pathological conditions has been reported. This revelation is imperative for both MDs and other muscle-wasting conditions, such as sarcopenia and cancer cachexia. The expression levels of miRNAs have immense potential for use as potential diagnostic, prognostic and therapeutic biomarkers. Understanding the role of miRNAs in muscle-wasting conditions may lead to the development of novel strategies for the improvement of patient management. |
| first_indexed | 2024-03-10T05:36:40Z |
| format | Article |
| id | doaj.art-be99b8c1fcc1451d9baa833db4878f33 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T05:36:40Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-be99b8c1fcc1451d9baa833db4878f332023-11-22T22:50:19ZengMDPI AGCells2073-44092021-11-011011303510.3390/cells10113035Therapeutic Implications of miRNAs for Muscle-Wasting ConditionsLaura Yedigaryan0Maurilio Sampaolesi1Translational Cardiomyology Laboratory, Stem Cell Biology and Embryology, Department of Development and Regeneration, KU Leuven, 3000 Leuven, BelgiumTranslational Cardiomyology Laboratory, Stem Cell Biology and Embryology, Department of Development and Regeneration, KU Leuven, 3000 Leuven, BelgiumMicroRNAs (miRNAs) are small, non-coding RNA molecules that are mainly involved in translational repression by binding to specific messenger RNAs. Recently, miRNAs have emerged as biomarkers, relevant for a multitude of pathophysiological conditions, and cells can selectively sort miRNAs into extracellular vesicles for paracrine and endocrine effects. In the overall context of muscle-wasting conditions, a multitude of miRNAs has been implied as being responsible for the typical dysregulation of anabolic and catabolic pathways. In general, chronic muscle disorders are associated with the main characteristic of a substantial loss in muscle mass. Muscular dystrophies (MDs) are a group of genetic diseases that cause muscle weakness and degeneration. Typically, MDs are caused by mutations in those genes responsible for upholding the integrity of muscle structure and function. Recently, the dysregulation of miRNA levels in such pathological conditions has been reported. This revelation is imperative for both MDs and other muscle-wasting conditions, such as sarcopenia and cancer cachexia. The expression levels of miRNAs have immense potential for use as potential diagnostic, prognostic and therapeutic biomarkers. Understanding the role of miRNAs in muscle-wasting conditions may lead to the development of novel strategies for the improvement of patient management.https://www.mdpi.com/2073-4409/10/11/3035skeletal muscle regenerationmiRNAsstem cellsepigeneticsinflammationmuscle injury |
| spellingShingle | Laura Yedigaryan Maurilio Sampaolesi Therapeutic Implications of miRNAs for Muscle-Wasting Conditions Cells skeletal muscle regeneration miRNAs stem cells epigenetics inflammation muscle injury |
| title | Therapeutic Implications of miRNAs for Muscle-Wasting Conditions |
| title_full | Therapeutic Implications of miRNAs for Muscle-Wasting Conditions |
| title_fullStr | Therapeutic Implications of miRNAs for Muscle-Wasting Conditions |
| title_full_unstemmed | Therapeutic Implications of miRNAs for Muscle-Wasting Conditions |
| title_short | Therapeutic Implications of miRNAs for Muscle-Wasting Conditions |
| title_sort | therapeutic implications of mirnas for muscle wasting conditions |
| topic | skeletal muscle regeneration miRNAs stem cells epigenetics inflammation muscle injury |
| url | https://www.mdpi.com/2073-4409/10/11/3035 |
| work_keys_str_mv | AT laurayedigaryan therapeuticimplicationsofmirnasformusclewastingconditions AT mauriliosampaolesi therapeuticimplicationsofmirnasformusclewastingconditions |